Design Therapeutics DSGN
NASDAQ DSGN
$11.16 +0.06 (+0.54%)
As of: Oct 21, 2026 · 10:23 AM EDT

Design Therapeutics (DSGN) EBIT Margin (2020)

Updated

Design Therapeutics (DSGN) reported EBIT Margin of -11700.00% for Q4 2020, up 215.00 percentage points from the prior quarter.

Analysis

Design Therapeutics (DSGN) EBIT Margin (2020) Analysis & Trends

For FY2020, Design Therapeutics posted EBIT Margin of -3685.84%.

  • Five-year quarterly EBIT Margin spans a low of -11915.00% in Q3 2020 and a high of -438.73% in Q1 2020.
  • Per Business Quant data, the three quarters before Q4 2020 came in at -11915.00% (Q3 2020), -4719.35% (Q2 2020) and -438.73% (Q1 2020).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin (Qtr)
1 Eli Lilly 1,132.34 Bn 1,100.93 Bn 19.71 Bn 51.16%
2 Johnson & Johnson 615.91 Bn 534.44 Bn 17.26 Bn 28.21%
3 AbbVie 505.47 Bn 478.59 Bn 12.70 Bn 37.86%
4 Merck 368.25 Bn 322.63 Bn 12.21 Bn -3.52%
5 Novartis Ag 298.18 Bn 262.17 Bn 11.24 Bn 32.97%
6 Astrazeneca 261.66 Bn 235.34 Bn 12.86 Bn 20.57%
7 Amgen 236.22 Bn 191.62 Bn 7.24 Bn 34.95%
8 Gilead Sciences 190.68 Bn 164.87 Bn 6.22 Bn -133.21%
9 Pfizer 170.14 Bn 116.79 Bn 10.94 Bn 28.37%
10 Design Therapeutics 697.56 Mn -158.47 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2020 -11,700.00%
Sep 30, 2020 -11,915.00%
Jun 30, 2020 -4,719.35%
Mar 31, 2020 -438.73%
API Access

Design Therapeutics EBIT Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebit-margin&ticker=DSGN&period=max&api_key=YOUR_API_KEY